PMID- 28677795
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20180723
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 38
IP  - 2
DP  - 2017 Aug
TI  - CtBP2 is associated with angiogenesis and regulates the apoptosis of prostate
      cancer cells.
PG  - 1259-1267
LID - 10.3892/or.2017.5763 [doi]
AB  - Angiogenesis is associated with prostate cancer (PCa) development and
      progression. Aberrant expression of C-terminal binding protein (CtBP)2 has been
      observed in PCa, but whether its change in expression plays a significant role in
      angiogenesis has not been completely characterized. we attempted to integrate and
      analyze the genome-wide association study (GWAS) of follicle stimulating hormone 
      receptor (FSHR) and CtBP2, the Cancer Genome Atlas (TCGA) data and CtBP2 binding 
      data in CistromeMap (18) to explore the mechanism of CtBP2 in PCa, and performed 
      pathway enrichment analysis. We revealed that the top 6 pathways were closely
      related with angiogenesis. We used siRNA and overexpression plasmids to silence
      and overexpress CtBP2 expression. Altered expression of CtBP2 affected the
      expression of VEGFA, FSHR, FHL2 and SMAD3 which are closely related with
      angiogenesis. In addition, silencing of CtBP2 markedly increased the apoptosis of
      PCa cells in vitro, and decreased the expression of IL-8, AT2R, CCND1 and MMP9
      which are associated with cancer progression. These results highlight the
      association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be 
      a potential therapeutic target for PCa.
FAU - Xuan, Qiang
AU  - Xuan Q
AD  - Department of Urology, Anhui Provincial Hospital Affiliated Anhui Medical
      University, Hefei, Anhui 230022, P.R. China.
FAU - Zhong, Xiaoge
AU  - Zhong X
AD  - Center for Genomic and Personalized Medicine, Guangxi Medical University,
      Nanning, Guangxi 530021, P.R. China.
FAU - Li, Weidong
AU  - Li W
AD  - Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi 530021,
      P.R. China.
FAU - Mo, Zengnan
AU  - Mo Z
AD  - Center for Genomic and Personalized Medicine, Guangxi Medical University,
      Nanning, Guangxi 530021, P.R. China.
FAU - Huang, Yuanjie
AU  - Huang Y
AD  - Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi 530021,
      P.R. China.
FAU - Hu, Yanling
AU  - Hu Y
AD  - Center for Genomic and Personalized Medicine, Guangxi Medical University,
      Nanning, Guangxi 530021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170628
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (FHL2 protein, human)
RN  - 0 (LIM-Homeodomain Proteins)
RN  - 0 (Muscle Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Receptors, FSH)
RN  - 0 (SMAD3 protein, human)
RN  - 0 (Smad3 Protein)
RN  - 0 (Transcription Factors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 1.1.- (Alcohol Oxidoreductases)
RN  - EC 1.1.- (CTBP2 protein, human)
SB  - IM
MH  - Alcohol Oxidoreductases/*genetics
MH  - *Apoptosis
MH  - Biomarkers, Tumor/*genetics
MH  - Cell Proliferation
MH  - Disease Progression
MH  - Gene Expression Regulation, Neoplastic
MH  - Genome-Wide Association Study
MH  - Humans
MH  - LIM-Homeodomain Proteins/genetics
MH  - Male
MH  - Muscle Proteins/genetics
MH  - Neovascularization, Pathologic/genetics/*pathology
MH  - Nerve Tissue Proteins/*genetics
MH  - Prostatic Neoplasms/*blood supply/genetics/*pathology
MH  - Receptors, FSH/genetics
MH  - Smad3 Protein/genetics
MH  - Transcription Factors/genetics
MH  - Tumor Cells, Cultured
MH  - Vascular Endothelial Growth Factor A/genetics
EDAT- 2017/07/06 06:00
MHDA- 2018/07/24 06:00
CRDT- 2017/07/06 06:00
PHST- 2016/10/28 00:00 [received]
PHST- 2017/05/08 00:00 [accepted]
PHST- 2017/07/06 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
PHST- 2017/07/06 06:00 [entrez]
AID - 10.3892/or.2017.5763 [doi]
PST - ppublish
SO  - Oncol Rep. 2017 Aug;38(2):1259-1267. doi: 10.3892/or.2017.5763. Epub 2017 Jun 28.